A Labeled Neutral Endopeptidase Inhibitor as a Potential Tool for Tumor Diagnosis and Prognosis | Zendy

Raguin Olivier | Zendy; FourniéZaluski MarieClaude | Zendy; Romieu Anthony | Zendy; Pèlegrin André | Zendy; Chatelet François | Zendy; Pélaprat Didier | Zendy; Barbet Jacques | Zendy; Roques Bernard P. | Zendy; GruazGuyon Anne | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

A Labeled Neutral Endopeptidase Inhibitor as a Potential Tool for Tumor Diagnosis and Prognosis

Author(s) -

Raguin Olivier,

FourniéZaluski MarieClaude,

Romieu Anthony,

Pèlegrin André,

Chatelet François,

Pélaprat Didier,

Barbet Jacques,

Roques Bernard P.,

GruazGuyon Anne

Publication year - 2005

Publication title -

angewandte chemie international edition

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.831

H-Index - 550

eISSN - 1521-3773

pISSN - 1433-7851

DOI - 10.1002/anie.200500700

Subject(s) - neprilysin , in vivo , chemistry , endopeptidase , enzyme , cancer research , biochemistry , medicine , biology , microbiology and biotechnology

Specific targeting of tumors with radioactive isotopes is the key for high‐sensitivity scintigraphy detection. A labeled neutral endopeptidase (NEP) inhibitor is described that accumulates in vivo in tumor cells expressing this enzyme, which makes it a potential tool for noninvasive evaluation of NEP expression. Its structure (black with the label depicted in red, DTPA=diethylenetriaminepentaacetic acid) is shown in a model of the NEP active site (blue).

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research